People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...
The company NextMed faces a $150,000 fine for fake weight loss claims and hidden costs. The FTC warns that promises like fast ...
You’ve probably heard of Ozempic, Wegovy, Zepbound, and Mounjaro. But if your algorithm serves up wellness and fitness ...
Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.
Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Pharmaceutical Technology on MSN
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...
The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback